The American Society of Hematology (#ASH18) annual meeting is has come to an end. Monday has been traditionally known as “Myeloma Madness Monday.” This year was no different. Oral sessions included topics on the combination therapies, #CAR-T and #BiTE (Bispecific T-cell Engager) therapy. Other potential new agents in #myeloma, like venetoclax, selinexor and isatuximab, were […]
December 3, 2018 Yes, today was the last full day of ASH, but that’s not to say it wasn’t full of information with oral presentations packing the day from 7:00 a.m.–7:45 p.m. Highlights included (# abstract number): Isatuximab-Vel-Rev-dex (Isa-VRd) for Newly Diagnosed Non-stem-cell-transplant-eligible myeloma patients (#595): This four-drug phase I study for 27 patients reported […]
CHARLIE BROWN: Someday we will die, Snoopy. SNOOPY: True, but all the other days, we will not. Snoopy’s philosophy resonates at ASH 2018 because of all the exciting information on immunotherapy. There are new approaches to the use of daratumumab with other agents in quadruple combinations that result in high rate of response in newly […]
Each year at the American Society of Hematology (ASH) annual meeting, I’ve been overwhelmed by the amount of research underway to bring new treatments and hopefully a cure to multiple myeloma patients. Thankfully, this year is no different; however, last night I was reminded just how far we’ve come in a relatively short period of […]
